You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Rhodes Pharms Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for RHODES PHARMS, and what generic and branded alternatives to RHODES PHARMS drugs are available?

RHODES PHARMS has twenty-eight approved drugs.

There are two tentative approvals on RHODES PHARMS drugs.

Summary for Rhodes Pharms
US Patents:0
Tradenames:20
Ingredients:18
NDAs:28

Drugs and US Patents for Rhodes Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rhodes Pharms DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 210651-003 May 17, 2019 AB1 RX No No ⤷  Sign Up ⤷  Sign Up
Rhodes Pharms OXYCODONE HYDROCHLORIDE oxycodone hydrochloride TABLET;ORAL 091490-004 Mar 9, 2011 AB RX No No ⤷  Sign Up ⤷  Sign Up
Rhodes Pharms THEOPHYLLINE theophylline TABLET, EXTENDED RELEASE;ORAL 040086-001 Apr 15, 1996 DISCN No No ⤷  Sign Up ⤷  Sign Up
Rhodes Pharms THEOPHYLLINE theophylline TABLET, EXTENDED RELEASE;ORAL 040086-002 Sep 1, 1982 AB RX Yes No ⤷  Sign Up ⤷  Sign Up
Rhodes Pharms DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 213111-003 Jan 13, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up
Rhodes Pharms DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 210651-002 May 17, 2019 AB1 RX No No ⤷  Sign Up ⤷  Sign Up
Rhodes Pharms AMPHETAMINE SULFATE amphetamine sulfate TABLET;ORAL 213852-002 Sep 7, 2021 AA RX No No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Rhodes Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-001 Apr 17, 2015 10,463,624 ⤷  Sign Up
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-004 Apr 17, 2015 10,463,624 ⤷  Sign Up
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-005 Apr 17, 2015 10,463,624 ⤷  Sign Up
Rhodes Pharms DILAUDID hydromorphone hydrochloride SOLUTION;ORAL 019891-001 Dec 7, 1992 6,589,960 ⤷  Sign Up
Rhodes Pharms APTENSIO XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 205831-007 Apr 17, 2015 10,463,624 ⤷  Sign Up
Rhodes Pharms DILAUDID hydromorphone hydrochloride TABLET;ORAL 019892-003 Nov 9, 2007 6,589,960 ⤷  Sign Up
Rhodes Pharms DILAUDID hydromorphone hydrochloride TABLET;ORAL 019892-001 Dec 7, 1992 6,589,960 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for RHODES PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 2015-12-23
➤ Subscribe Extended-release Capsules 15 mg, 20 mg, 40 mg and 50 mg ➤ Subscribe 2015-12-28
➤ Subscribe Oral Solution 5 mg/5mL ➤ Subscribe 2011-02-25
➤ Subscribe Tablets 2 mg, 4 mg, and 8 mg ➤ Subscribe 2013-08-05
➤ Subscribe Extended-release Capsules 10 mg ➤ Subscribe 2015-12-24
➤ Subscribe Extended-release Capsules 30 mg ➤ Subscribe 2016-03-28
➤ Subscribe Injection 2 mg/mL ➤ Subscribe 2011-06-22
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.